Trump to pharmaceutical enterprises: Transport manufacturing to America or facing customs duties in the face

During a special meeting, US President Donald Trump warned pharmaceutical companies that customs duties were imminent, and called on companies to accelerate the transfer of their production from abroad to the United States, according to two people familiar with the conversation. At the same time, Trump did not meet the congress to reduce the pharmaceutical pricing program approved during the Joe Biden government, the program that tried to amend pharmaceutical businesses. Trump’s tone reflects that the pharmaceutical sector efforts to earn its support can be more difficult than executive officials expected. Despite his supportive position of the business sector, his relationship with pharmaceutical businesses was tense during his first term, because he accused them of a time of impunity in terms of medicine prices. The claims of the pharmaceutical sector, Trump, met in the White House on Thursday, with a number of managers in the sector, including David Rex, CEO of Eli Lilly & Co., Robert Davis, CEO of Merck & Co, and Fayzer CEO Albert Burla. (Pfizer), in addition to Stephen Opel, head of the largest pressure group in the pharmaceutical industry. The purpose of the meeting was to persuade Trump to support the reducing law that the federal government gives the authority to negotiate the prices of some medicines, as well as the support for the policy to reduce the influence of mediators, which hold the industry responsible for the high costs that patients directly bear. Executive officials also called on Trump’s support to unite the time tables in which medicine was excluded from the price negotiation program. These tables differ between complex and manufactured medicines in the form of pills at a lower cost, which the industry sees that it can negatively affect the incentives for the development of medicine. Trump criticizes the prices of medicines that people who are familiar with the meeting said that Trump is not committed to approving the request of pharmaceutical businesses. The US president has expressed concern that any changes in pharmaceutical policies could hinder the efforts of Republicans in the passing of tax reforms. Trump on Friday renewed his complaints he launched during his first term over the high cost of medication prescribed in the United States compared to other countries. During the statements of the White House, he explained that the Minister of Health and Humanitarian Services, Robert F. Kennedy Junior, along with Mohamed Oz, his candidate is to lead health care centers and medical services, is reducing medicine prices. “I hope you focus a lot on the costs too, because the Americans are exploited, and it is unacceptable and we won’t allow it,” Trump said. He added that the United States citizens pay more for the same prescribed medication compared to London, without specifying the names of specific medicines. The Biden Pharmacy Program continued at the same time, health care officials on Friday confirmed that they would continue to implement the next phase of the negotiating program on the prices of medicines launched during the Biden era, in another indication that the efforts of pharmaceutical businesses to change this program have not made progress. The next negotiation of prices includes drugs such as “Ozempic” and “Wegovy”, which are used to lose weight. Despite Trump’s previous criticism of the industry, and his choice of Kennedy, known for his acceptance of controversial theories about vaccines and medicine, the managers expressed their optimism about Trump’s second state.